Innovation in European healthcare – what can Sweden learn? - LIF

Ixico, a world-class medical imaging company has won
a significant funding amount of £2.1 million from the
Biomedical Catalyst Fund
• The London-based medical imaging company Ixico and the British
developer of neuropsychological tests, Cambridge Cognition were
awarded a grant from the Biomedical Catalyst Fund in November
2012.
• Ixico will work alongside Cambridge Cognition, a leading UK
developer of neuropsychological tests, and their projected partners at
King’s College London, University of Sussex and Imperial College
London.
• The grant will fund a project to build and test a novel digital healthcare
platform, which will provide an earlier, more accurate, and costeffective
diagnosis of dementia.
• The three year collaborative project aims to demonstrate a significant
decrease in the diagnosis of dementia – from an average of 18
months to just 3 months, thus enabling patients to access
timely treatment.
• World-class computer-based tests of memory and thinking will be
integrated with computerised analysis of MRI brain scans, to make
automated and accurate diagnostic reports that lead to rapid
treatment for patient.
200